Publisher Correction: Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance

Correction to: Scientific Reports 10.1038/s41598-022-08012-7, published online 10 March 2022

The original version of this Article contained errors in Table 1 where the data was listed incorrectly in the column ‘M-KRAS patients’. The original Table 1 and accompanying legend appear below.

Table 1.

Parameters values of the developed model characterizing the dynamics of tumor size and mutation concentrations in metastatic colorectal cancer (mCRC) patients.

Parameters (units)	Description	Typical values		Reference
		WT-KRAS patients	M-KRAS patients
$T_{s\_0}$(mm2)	Baseline of $T_s$ (clonal population that is sensitive to anti-EGFR inhibitor ($D_1$) )	5500	100	Data/Estimated value; Mutation was assumed to be acquired during treatment
$T_{R1\_0}$(mm2)	Baseline of $T_{R1}$ (clonal population that is resistance to $D_1$ but is sensitive to the second hypothetical treatment ($D_2$))	0	1700	Data/Estimated value; Mutation was assumed to be acquired during treatment
$T_{R2\_0}$(mm2)	Baseline of $T_{R2}$ (clonal population that is resistance to both treatments)	0	0	Data/Estimated value; Mutation was assumed to be acquired during treatment
$M_{ctDNA1\_0}$(fragments/ml)	Baseline of mutant KRAS $\left(M_{ctDNA1}\right)$ in ctDNA	0	500	Data/Estimated value; Mutation was assumed to be acquired during treatment
$M_{ctDNA2\_0}$(fragments/ml)	Baseline of a second hypothetical mutation $\left(M_{ctDNA2}\right)$ in ctDNA	0	0	Data/Estimated value; Mutation was assumed to be acquired during treatment
$k_{g1}$(/week)	Growth rate constant of $T_s$	0.03		40
$k_{g2}$(/week)	Growth rate constant of $T_{R1}$	0.021		43,44
$k_{g3}$(/week)	Growth rate constant of $T_{R2}$	0.015		43,44
$k_{s1}$(/week)	Tumor shrinkage rate constant due to $D_1$	0.1		Estimated value
$k_{s2}$(/week)	Tumor shrinkage rate constant due to $D_2$	0.1		$k_{s1}$
$k_{M1}$(/week)	Mutation rate from $T_s$ to $T_{R1}$ when $D_1$ = 1	0.05		Estimated value
$k_{M2}$(/week)	Mutation rate from $T_{R1}$ to $T_s$ when $D_1$ = 0	0.03		Lower than $k_{M1}$ 9
$k_{M3}$(/week)	Mutation rate from $T_{R1}$ to $T_{R2}$ when $D_2$ = 1	0.05		$k_{M1}$
$k_{M4}$(/week)	Mutation rate from $T_{R2}$ to $T_{R1}$ when $D_2$ = 0	0.03		$k_{M2}$
$H$	Hill coefficient	5		Visually matching the slope of data and the detectable time of mutant KRAS
$K{T}_{50}$(mm2)	The size of tumor that provide half-maximal shedding rate of ctDNA	3500		Visually matching the slope of data and the detectable time of mutant KRAS
$k_{\text{max}\_1}$((fragments/ml)/(week*mm2))	Maximum shedding rate of $M_{ctDNA1}$	0.015	1.5	Visually matching the slope of data and the detectable time of mutant KRAS
$k_e$(/week)	ctDNA eliminate rate constant	0.5		Visually matching the slope of data and the detectable time of mutant KRAS
$k_{\text{max}\_2}$((fragments/ml)/(week*mm2))	Maximum shedding rate of $M_{ctDNA2}$	0.015	1.5	$k_{\text{max}\_1}$
IIV_ $B$ (${\omega }_1$)	Standard deviation of IIV of baselines	0.6		Data
IIV_ $k_g$ (${\omega }_2$)	Standard deviation of IIV of $k_g$	0.2		Data

ctDNA, circulating tumor DNA; IIV, interindividual variability; WT-KRAS patients, patients who were initially identifed as KRAS wild-type in ctDNA; M-KRAS patients, patients who had detectable mutant KRAS in ctDNA pre-treatment.

The original Article has been corrected.